

Financial Tear Sheet

Corporate Profile

POZEN Inc., headquartered in Chapel Hill, NC, is a pharmaceutical company committed to transforming medicines that transform lives. Since its founding in 1996, POZEN has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Moving forward, POZEN is poised to become a model 21st century pharmaceutical company dedicated to ensuring that they produce cost-effective, evidence-based medicines; take a fresh approach to sales, marketing and medical education; and deliver high-quality, affordable pharmaceuticals to their customers. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.

Primary IR Contact

Nichol Ochsner
Investor Relations
Phone: (919) 913-1030
E-mail:
nochsner@pozen.com

[UBS Global Life Sciences Conference](#)

September 21, 2009

[Click here for Thomas Weisel Partners 2009 Healthcare Conference](#)

September 10, 2009

[Click here for ACG Slide Presentation](#)

November 2, 2005

Stock Performance

POZN (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$6.13
Change (%)	▲ 0.19 (3.20%)
Volume	304,781
52 Week Low	\$5.27
Market Cap	\$0
Rolling EPS	-0.54
PE Ratio	N/A

Shares Outstanding 0

Data as of 03/09/16 4:00 p.m. ET

Chart is not available for this symbol

Recent Headlines & Events

February 05, 2016 - 1:18 p.m.

[POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.](#)

February 02, 2016 - 9:01 a.m.

[POZEN Inc. Announces Stockholder Approval of its Transaction with Tribute Pharmaceuticals Canada Inc.](#)


December 28, 2015 - 9:05 a.m.

[POZEN Announces Effectiveness Of Aralez Registration Statement On Form S-4 And Provides Update On Key Milestones For 2016](#)

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: 2.0



Unable to fulfill request.

SEC Filings

Filing Date	Form
02/06/19	8-K
01/18/19	8-K
12/12/18	8-K
11/02/18	8-K

Corporate Governance

John R. Plachetka, Pharm.D	Chairman President and Chief Executive Officer
Matthew E. Czajkowski	Chief Financial Officer, Senior Vice President, Finance and Administration
Andrew L. Finn, Pharm.D.	Executive Vice President, Product Development
Kristina M. Adomonis	Senior Vice President, Business Development
John E. Barnhardt	Vice President, Finance and Administration
Donna L. Gilbert, Ph.D.	Vice President, Pharmaceutical Development
Dennis L. McNamara	Vice President, Business Development

Minimum 20 minutes delayed